Allogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Purchased by Creative Planning

Creative Planning increased its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 108.7% during the 3rd quarter, Holdings Channel.com reports. The fund owned 61,396 shares of the company’s stock after acquiring an additional 31,984 shares during the period. Creative Planning’s holdings in Allogene Therapeutics were worth $172,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD lifted its stake in Allogene Therapeutics by 76.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,177,619 shares of the company’s stock worth $18,675,000 after acquiring an additional 1,806,147 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Allogene Therapeutics by 340.4% during the 2nd quarter. Renaissance Technologies LLC now owns 1,747,955 shares of the company’s stock worth $4,073,000 after acquiring an additional 1,351,055 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Allogene Therapeutics by 24.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock valued at $5,944,000 after purchasing an additional 507,021 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Allogene Therapeutics by 70.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 480,381 shares of the company’s stock valued at $1,119,000 after purchasing an additional 198,231 shares in the last quarter. Finally, Primecap Management Co. CA raised its position in Allogene Therapeutics by 4.1% in the 2nd quarter. Primecap Management Co. CA now owns 5,670,226 shares of the company’s stock valued at $13,212,000 after purchasing an additional 221,840 shares in the last quarter. Institutional investors and hedge funds own 83.63% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ALLO. Oppenheimer began coverage on Allogene Therapeutics in a research report on Thursday, August 8th. They issued an “outperform” rating and a $11.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price target on shares of Allogene Therapeutics in a research report on Friday. Citigroup increased their price target on Allogene Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Truist Financial reiterated a “buy” rating and issued a $14.00 price objective (down previously from $17.00) on shares of Allogene Therapeutics in a report on Friday, August 9th. Finally, Canaccord Genuity Group dropped their price objective on Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Allogene Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $9.96.

Allogene Therapeutics Trading Up 0.3 %

Allogene Therapeutics stock opened at $3.09 on Tuesday. The stock has a 50 day moving average of $2.74 and a two-hundred day moving average of $2.66. The stock has a market capitalization of $646.15 million, a price-to-earnings ratio of -1.98 and a beta of 0.84. Allogene Therapeutics, Inc. has a twelve month low of $2.01 and a twelve month high of $5.78.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).